Latest in Schizophrenia
Sort by
4 items
-
AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie’s “pain” is Bristol Myers Squibb’s “gain,” says Truist Securities analyst Srikripa Devarakonda.Business - MarketWatch - November 12 -
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.Business - MarketWatch - November 11 -
AbbVie shares tumble after schizophrenia drug disappoints
US pharma group says patients who took Emraclidine in clinical trials failed to show a significant decline in symptomsBusiness - Financial Times - November 11 -
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the researchHealth - ABC News - October 31